| General Information |
| Business: |
We are a blank check company. We intend to focus on the healthcare or healthcare-related industries. (Incorporated in the Cayman Islands)
In particular, we will target North American or European companies in the life sciences and biotechnology sectors where our management has extensive investment experience. We will search for a target company in these sectors with a valuation between $300 million and $500 million.
Stone Capital Partners, LLC, is our sponsor.
(Note: Translational Development Acquisition Corp. filed its S-1 on Aug. 26, 2022, with terms: 15 million units at $10 each to raise $150 million; the company filed confidential IPO documents on June 13, 2022. Each unit consists of one share of common stock and one-half of a warrant. Each whole warrant can be redeemed to buy one share of common stock.)
|
| Industry: |
BLANK CHECK |
| Employees: |
0 |
| Founded: |
2022 |
| Contact Information |
| Address |
1270 Avenue of the Americas 24th Floor New York, NY 10020 |
| Phone Number |
(917) 979-3072 |
| Web Address |
|
| View Prospectus: |
Translational Development Acquisition Corp. |
| Financial Information |
| Market Cap |
$190.5mil |
| Revenues |
$0 mil (last 12 months) |
| Net Income |
$0 mil (last 12 months) |
| IPO Profile |
| Symbol |
TDACU |
| Exchange |
NASDAQ |
| Shares (millions): |
15.0 |
| Price range |
$10.00 - $10.00 |
| Est. $ Volume |
$150.0 mil |
| Manager / Joint Managers |
BTIG, LLC |
| CO-Managers |
|
| Expected To Trade: |
12/23/2024 |
|
Day:
|
Monday |
| Quiet Period Expiration Date: |
Available only to Subscribers |
| Lock-Up Period Expiration Date: |
Available only to Subscribers |
| SCOOP Rating |
Available only to Subscribers |
| Rating Change |
Available only to Subscribers |
